Status:
COMPLETED
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986446 in healthy participants including healthy participants of Japanese ethnicity.
Eligibility Criteria
Inclusion
- Participant must be of Japanese ethnicity (both biological parents are ethnically Japanese) for Part 1 and Part 2, Panel 2. No limitations on ethnicity apply to Part 2, Panel 1
- Participant is healthy, without any significant abnormalities in medical history, physical examination, ECGs, or clinical laboratory assessments determinations, as assessed by the investigator
- Body mass index (BMI) of at least 18 kg/m\^2 but no more than 32 kg/m\^2 at screening
- Body weight between 45 kg and 110 kg
Exclusion
- Any clinically significant deviation from normal, as judged by the investigator
- Any major surgery within 90 days of study drug administration
- Participation in another interventional clinical trial concurrent with this study
- Note: Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
October 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 8 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06084598
Start Date
October 12 2023
End Date
March 8 2024
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Cypress, California, United States, 90630